TLDR
- Novo Nordisk is rebranding to “Novo” with a new tagline: “Lasting Health Starts Now”
- NVO stock is down about 15% this year despite strong oral Wegovy sales
- The company holds 38.8% obesity market share vs. Eli Lilly’s 60.9% in Q2
- A new cultural framework called “The Novo Way” outlines four operating principles
- Full business strategy details will be revealed at Capital Markets Day on September 21 in London
Novo Nordisk is turning the page. The Danish drugmaker announced Monday it is rebranding to “Novo” and overhauling its corporate culture as it works to claw back market share in the obesity drug space.
NVO stock was trading down 2.14% at the time of writing, and is down roughly 15% year-to-date, even as the oral version of Wegovy surpassed 3 million prescriptions as of June.
The rebrand centres on the phrase “Lasting Health Starts Now,” a push to make the company more relevant to everyday patients and build trust with the public.
“Novo Nordisk A/S” stays as the legal name globally. The “Novo” shorthand will be used day-to-day, alongside an updated visual identity that keeps the Apis bull logo from the company’s heritage.
CEO Mike Doustdar said the company’s purpose isn’t changing. “We remain true to our purpose of changing people’s lives and are ambitious about our future to help them have lasting health, starting right now,” he said.
The Novo Way
The cultural overhaul, called “The Novo Way,” is built on four principles: customer obsession, competitiveness, clarity, and care and integrity.
The framework is aimed at helping Novo move faster in a market that’s become more competitive and increasingly consumer-driven.
Tania Sabroe, EVP of People, Organisation and Corporate Affairs, said culture and brand work together. “Our updated culture will enable us to move with focus and speed,” she said.
The Market Share Problem
The rebrand comes as Novo faces real pressure from Eli Lilly. Novo held just 38.8% of the obesity drug market in Q2, compared to Lilly’s 60.9%, according to IQVIA data cited in a Lilly earnings presentation.
The company recently cancelled three trials for an experimental cardiovascular drug, adding to investor concerns.
Oral Wegovy has been a bright spot, launching ahead of Lilly’s competing weight loss pill, Foundayo. The head start gave Novo some breathing room in the direct-to-consumer space.
The full strategic picture will come into focus at Novo’s Capital Markets Day on September 21 in London, where management will lay out its updated business strategy.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
